Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

Jennifer Bellon, MD
Published: Friday, Jul 29, 2016


Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

The LUMINA trial in Canada is evaluating the risk of local recurrence following breast-conserving surgery and endocrine therapy in low-risk Luminal A breast cancer.

The IDEA trial, which is being conducted at the University of Michigan, is using oncotype score to pick a favorable group of patients.

The PRECISION trial is using PAM50 to identify breast cancer patients with Luminal A disease that may be candidates for breast-conserving surgery without adjuvant radiotherapy.

However, despite these ongoing studies, the current standard of treatment for patients under 70 in this space still includes radiation therapy.

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

The LUMINA trial in Canada is evaluating the risk of local recurrence following breast-conserving surgery and endocrine therapy in low-risk Luminal A breast cancer.

The IDEA trial, which is being conducted at the University of Michigan, is using oncotype score to pick a favorable group of patients.

The PRECISION trial is using PAM50 to identify breast cancer patients with Luminal A disease that may be candidates for breast-conserving surgery without adjuvant radiotherapy.

However, despite these ongoing studies, the current standard of treatment for patients under 70 in this space still includes radiation therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x